Dyne Therapeutics Inc. (DYN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
Dyne Therapeutics (DYN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
Does Dyne Therapeutics, Inc. (DYN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
Dyne Therapeutics (DYN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?
Dyne Therapeutics stock (NASDAQ NASDAQ : DYN), a biotechnology company focused on advancing genetically driven muscle diseases therapeutics, saw a significant 28% rise on Monday, May 20. This move came in after the company released a positive clinical trial data for its experimental drugs – DYNE-101 – for patients with myotonic dystrophy type 1, and DYNE-251 – for patients with Duchenne muscular dystrophy.
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.
